The World Health Organization released its first guidelines on medical treatment for obesity, explicitly recommending long‑term use of GLP‑1 receptor agonists as part of chronic disease management. The guidance reframes obesity as a persistent, biologically driven condition and advises clinicians to consider pharmacotherapy alongside lifestyle interventions. The WHO noted limitations in long‑term safety evidence for GLP‑1s but nonetheless recommended their use where appropriate, emphasizing the need for ongoing monitoring and comprehensive care. The guidance is likely to influence national payers, clinical practice, and commercial strategies for GLP‑1 manufacturers as regulatory and reimbursement debates continue. The document reinforces a global shift toward medical management of obesity and may accelerate demand for next‑generation metabolic medicines, while underscoring the need for more robust long‑term safety and effectiveness data.